Form 4 for LCTX Lineage Cell Therapeutics, Inc.
Accepted 2022-06-30 00:00:00 ET · period of report 2022-06-30 · accession 0001493152-22-018271 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-30 | 2022-06-30 | LCTX | Culley Brian M | Pres, CEO, Dir | M - OptEx | — | +15.4K | 113.2K | +16% | — |
| D | 2022-06-30 | 2022-06-30 | LCTX | Culley Brian M | Pres, CEO, Dir | F - Tax | $1.58 | -5,343 | 107.9K | -5% | -$8,442 |
| D | 2022-06-30 | 2022-06-30 | LCTX | Culley Brian M | Pres, CEO, Dir | M - OptEx | $0.00 | -15.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares, no par value | 2022-06-30 | M | A | 15,450 | — | 113,237 | D | — | — | (F1) Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis. (F2) Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. |
| 2 | Common | Common Shares, no par value | 2022-06-30 | F | D | 5,343 | $1.58 | 107,894 | D | — | — | (F3) Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. (F2) Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. |
| 3 | Derivative | Restricted Stock Units | 2022-06-30 | M | D | 15,450 | $0.00 | 0 | D | $0.00 · — to — | 15,450 Common Shares | (F4) The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. |